FDA accepts letter of intent for 1st AI drug development tool

The FDA’s Center for Drug Evaluation and Research has accepted the first letter of intent for an in silico drug development tool into the agency’s Innovative Science and Technology Approaches for New Drugs qualification program. The tool, an AI-Driven Digital Liver Model for Prediction of Drug-Induced Liver Injury, is designed to help predict liver toxicity […] The post FDA accepts letter of intent for 1st AI drug development tool appeared first on Becker's Hospital Review...